Generic Vafseo Availability

Last updated on Jan 8, 2025.

Vafseo is a brand name of vadadustat, approved by the FDA in the following formulation(s):

VAFSEO (vadadustat - tablet;oral)

Manufacturer: AKEBIA
Approval date: March 27, 2024
Strength(s): 150MG ^[RLD], 300MG ^[RLD], 450MG ^[RLD]

Has a generic version of Vafseo been approved?

No. There is currently no therapeutically equivalent version of Vafseo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vafseo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Patent 10,149,842
Issued: December 11, 2018
Inventor(s): Copp James Densmore & Newman Ann W. & Luong Anne
Assignee(s): Akebia Therapeutics, Inc.
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Patent expiration dates:
- November 14, 2034
  ✓
  Drug substance
  ✓
  Drug product
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Patent 11,065,237
Issued: July 20, 2021
Inventor(s): Copp James Densmore & Newman Ann W. & Luong Anne
Assignee(s): Akebia Therapeutics, Inc.
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Patent expiration dates:
- November 14, 2034
  ✓
  Patent use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
  ✓
  Drug substance
  ✓
  Drug product
Patent 11,324,734
Patent expiration dates:
- March 31, 2036
  ✓
  Drug product
Patent 11,844,756
Patent expiration dates:
- March 31, 2036
  ✓
  Patent use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Patent 11,857,543
Patent expiration dates:
- June 9, 2034
  ✓
  Patent use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Patent 7,811,595
Patent expiration dates:
- March 13, 2028
  ✓
  Drug substance
  ✓
  Drug product
Prolyl hydroxylase inhibitors and methods of use
Patent 8,323,671
Issued: December 4, 2012
Inventor(s): Wu Shengde & Warshakoon Namal C. & Evdokimov Artem G. & Greis Kenneth D. & Boyer Angelique Sun & Kawamoto Richard Masaru
Assignee(s): Akebia Therapeutics Inc.
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Patent expiration dates:
- April 3, 2028
  ✓
  Patent use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Prolyl hydroxylase inhibitors and methods of use
Patent 8,343,952
Issued: January 1, 2013
Inventor(s): Wu Shengde & Warshakoon Namal C. & Evdokimov Artem G. & Greis Kenneth D. & Boyer Angelique Sun & Kawamoto Richard Masaru
Assignee(s): Akebia Therapeutics Inc.
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Patent expiration dates:
- August 14, 2027
  ✓
  Drug substance
  ✓
  Drug product
Prolyl hydroxylase inhibitors and methods of use
Patent 8,598,210
Issued: December 3, 2013
Inventor(s): Kawamoto Richard Masaru & Wu Shengde & Warshakoon Namal C. & Evdokimov Artem G. & Greis Kenneth D. & Boyer Angelique Sun
Assignee(s): Akebia Therapeutics, Inc.
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Patent expiration dates:
- June 26, 2027
  ✓
  Drug substance
  ✓
  Drug product
Prolyl hydroxylase inhibitors and methods of use
Patent 8,940,773
Issued: January 27, 2015
Inventor(s): Kawamoto Richard Masaru & Wu Shengde & Evdokimov Artem G. & Greis Kenneth D. & Boyer Angelique Sun & Warshakoon Namal C.
Assignee(s): Akebia Therapeutics, Inc.
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Patent expiration dates:
- June 26, 2027
  ✓
  Patent use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Patent 9,701,636
Issued: July 11, 2017
Inventor(s): Copp James Densmore & Newman Ann W. & Luong Anne
Assignee(s): Akebia Therapeutics, Inc.
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Patent expiration dates:
- November 14, 2034
  ✓
  Drug substance
  ✓
  Drug product
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Patent 9,987,262
Issued: June 5, 2018
Inventor(s): Copp James Densmore & Newman Ann W. & Luong Anne
Assignee(s): Akebia Therapeutics, Inc.
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Patent expiration dates:
- November 14, 2034
  ✓
  Patent use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Prolyl hydroxylase inhibitors and methods of use
Patent RE47437
Issued: June 18, 2019
Inventor(s): Kawamoto Richard Masaru & Wu Shengde & Evdokimov Artem G. & Greis Kenneth D. & Boyer Angelique Sun & Warshakoon Namal C.
Assignee(s): Akebia Therapeutics, Inc.
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Patent expiration dates:
- June 26, 2027
  ✓
  Drug substance
  ✓
  Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- March 27, 2029 - NEW CHEMICAL ENTITY

More about Vafseo (vadadustat)

Patient resources

Vafseo drug information

Professional resources

Related treatment guides

Anemia Due to Chronic Kidney Disease

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Approval History Drug history at FDA

User Reviews & Ratings

Review this drug

Images

Pill VDT 300 is Vafseo 300 mg — Vafseo 300 mg (VDT 300)